CINCINNATI– CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension. The additional funds from existing investors, including Perceptive Advisors and CinRx Pharma, bring the Series B raise total to $59 million. The capital will support the ongoing enrollment and evaluation of deudomperidone in the Phase 2 envision3D study in adults with diabetic gastroparesis and position the company for registrational trials.
Gastroparesis is an area of high unmet medical need, impacting an estimated 12-16 million people in the U.S. alone, with an incidence rate growing on pace with diabetes and no U.S. Food and Drug Administration (FDA) approved long-term treatment option. CinDome’s deudomperidone is a new chemical entity being evaluated to address the unmet need in gastroparesis as a novel formulation of domperidone, a frequently prescribed first-line therapy for nausea, vomiting and gastroparesis outside of the U.S.
“This increased investment in CinDome extends our important, ongoing development activities and enables readiness for deudomperidone to enter late-stage trials,” said Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma. “We are grateful for the continued support and partnership from Perceptive Advisors to advance this high-impact therapeutic and bring a new hope to people impacted by gastroparesis.”
Deudomperidone is a new chemical entity based upon deuteration and novel formulation of domperidone, a frequently prescribed first-line therapy for nausea, vomiting and gastroparesis outside of the U.S. In part due to safety concerns around QT prolongation, domperidone is not approved in the U.S. Deudomperidone has been engineered to alter the PK profile for sustained efficacy while significantly reducing cardiac liability. Multiple clinical trials of deudomperidone demonstrated it was well tolerated, including no sponsor-assessed drug related adverse events (AEs) or clinically meaningful laboratory abnormalities. Deudomperidone was deemed to have no meaningful impact on QT at exposures well above a therapeutic dose in a thorough QT study and demonstrated target engagement and improvement in gastric emptying time in a previous Phase 2a trial.
